Advances in Treatment of Obstructive Hypertrophic Cardiomyopathy

EP. 1: Overview of Hypertrophic Cardiomyopathy

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

May 6th 2022

Martin S. Maron, MD, discusses the incidence and prevalence of hypertrophic cardiomyopathy and age of disease expression.

EP. 2: Role of Genetic Mutations in HCM Pathophysiology

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

May 6th 2022

Steve R. Ommen, MD, leads a review of common mutations seen in hypertrophic cardiomyopathy and the role of biomarkers and genetic testing in HCM.

EP. 3: Symptoms of Hypertrophic Cardiomyopathy

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

May 31st 2022

Drs Steve R. Ommen, Martin S. Maron, John A. Spertus, Javed Butler, and James Januzzi provide insight on the presentation of nonobstructive and obstructive hypertrophic cardiomyopathy.

EP. 4: The Effect of Obstructive Hypertrophic Cardiomyopathy on Health Status

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

May 31st 2022

John A. Spertus, MD, MPH, comments on the effect of oHCM on health status and quality of life for patients.

EP. 5: AHA/ACC HCM Guidelines and Patient Identification and Management

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

May 31st 2022

Steve R. Ommen, MD; and Martin S. Maron, MD, review the role of AHA/ACC guidelines, imaging techniques, and circulating biomarkers in approaching the diagnosis and treatment of hypertrophic cardiomyopathy.

EP. 6: Treatment Approaches for HCM

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

May 31st 2022

Drs Javed Butler, Martin S. Maron, Steve R. Ommen, and James Januzzi provide insight on approaching treatment of HCM with pharmacologic and nonpharmacologic interventions.

EP. 7: Invasive Treatments and Challenges with HCM Treatments

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

May 31st 2022

Experts in cardiology review invasive treatments, challenges with HCM treatments, and how to optimize treatment for patients.

EP. 8: Approaching Treatment Selection for Hypertrophic Cardiomyopathy

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

June 1st 2022

Steve R. Ommen, MD, leads a discussion on factors to consider when choosing treatment for hypertrophic cardiomyopathy (HCM).

EP. 9: Emerging Therapies for oHCM

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

June 1st 2022

Steve R. Ommen, MD, discusses the use of novel agents in the pipeline for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

EP. 10: EXPLORER-HCM Trial in oHCM

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

June 1st 2022

John A. Spertus, MD, MPH, and Martin S. Maron, MD comment on the role of mavacamten in oHCM as seen in the EXPLORER-HCM trial.

EP. 11: Health Status With Different HCM Treatments

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

June 1st 2022

Cardiac specialists discuss improvement in health status with different treatments for hypertrophic cardiomyopathy.

EP. 12: Long-Term Data of Mavacamten Use in oHCM

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

June 1st 2022

Martin S. Maron, MD, examines long-term data with mavacamten for oHCM treatment that was presented at ACC 2022.

EP. 13: VALOR-HCM Study in oHCM

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

June 1st 2022

A panel of experts in cardiovascular medicine review the use of mavacamten as seen in the VALOR-HCM study for patients with symptomatic oHCM who are eligible for septal reduction therapy.

EP. 14: Future Directions for oHCM Treatment

ByJames Januzzi, MD,Steve R. Ommen, MD,John A. Spertus, MD, MPH,Martin S. Maron, MD,Javed Butler, MD, MPH, MBA

June 1st 2022

Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.